Welcome to our dedicated page for BOUNDLESS BIO news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on BOUNDLESS BIO stock.
Boundless Bio, Inc. (Nasdaq: BOLD) is a clinical-stage oncology company whose news flow centers on the development of ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers. Company press releases highlight progress in its Phase 1/2 POTENTIATE trial, which evaluates the oral CHK1 inhibitor BBI-355 and, more recently, a combination arm pairing BBI-355 with the oral RNR inhibitor BBI-825 in patients with oncogene-amplified tumors.
Investors following BOLD news can expect regular updates on clinical development milestones, including enrollment status, portfolio prioritization decisions, and the evolution of Boundless Bio’s therapeutic strategy. The company has reported decisions to discontinue certain BBI-355 monotherapy and combination arms, while prioritizing a novel combination of BBI-355 and BBI-825 based on preclinical evidence of synergistic anti-tumor activity and a dosing approach that seeks to avoid overlapping toxicity.
News releases also cover the advancement of BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader targeting ecDNA segregation and inheritance. Boundless Bio communicates its plans for IND-enabling studies and anticipated IND submission timelines for BBI-940, along with broader pipeline activities supported by its Spyglass platform. In addition, the company issues quarterly and annual financial results and provides commentary on its cash runway and operational priorities, framed as forward-looking statements subject to risks described in its SEC filings.
Another recurring theme in BOLD news is conference participation and scientific presentations. Boundless Bio announces appearances at healthcare investor conferences and oncology meetings, such as the Goldman Sachs Global Healthcare Conference, the Needham Virtual Healthcare Conference, the Piper Sandler Annual Healthcare Conference, and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. These events often feature fireside chats or poster presentations on BBI-355, BBI-825, and the BBI-940 kinesin program.
For readers tracking BOLD, this news page aggregates company-issued updates on clinical trials, ecDTx pipeline progress, financial reporting, and investor and scientific conference activity related to Boundless Bio’s focus on extrachromosomal DNA (ecDNA) biology.
Boundless Bio (BOLD) has reported its Q4 and full year 2024 financial results, highlighting progress in its oncology pipeline targeting extrachromosomal DNA (ecDNA) in cancer treatment. The company's lead candidate, BBI-355, is advancing in the Phase 1/2 POTENTIATE trial, with initial proof-of-concept data expected in H2 2025.
Key financial metrics include a strong cash position of $152.1 million as of December 31, 2024, providing runway into 2027. Full-year 2024 results showed R&D expenses of $55.3 million and G&A expenses of $18.0 million, with a net loss of $65.4 million.
The company is also progressing with its novel Kinesin program, targeting ecDNA segregation, with development candidate nomination expected by mid-2025 and IND submission planned for H1 2026. Additionally, Boundless appointed Robert Doebele, M.D., Ph.D., as Chief Medical Officer in February 2025.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology research for treating oncogene amplified cancers, has announced its participation in the upcoming Leerink Global Healthcare Conference.
The company's President and CEO, Zachary Hornby, will engage in a fireside chat session scheduled for March 12, 2025, at 11:20 a.m. ET in Miami, FL. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website under the Events & Presentations section in the Investors area.
Boundless Bio (Nasdaq: BOLD) has appointed Robert ('Bob') Doebele, M.D., Ph.D., as Chief Medical Officer. Dr. Doebele brings over 15 years of oncology drug development experience to the clinical-stage oncology company, which focuses on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers.
Dr. Doebele was previously co-founder and Chief Scientific and Medical Officer at Rain Oncology (acquired by Pathos AI), where he led development of precision oncology therapies. His notable achievements include leading research at the University of Colorado that pioneered the TRK inhibitor field, contributing to the approval of Vitrakvi® and Rozlytrek®.
At Boundless Bio, Dr. Doebele will oversee the advancement of the BBI-355 Phase 1/2 POTENTIATE trial and the selection of a development candidate for the company's Kinesin program.
Boundless Bio (BOLD) announced significant updates to its pipeline and leadership team. The company has decided not to advance BBI-825 into Part 2 of the STARMAP trial due to pharmacokinetic data concerns and increasing development costs. However, enrollment continues for BBI-355's Phase 1/2 POTENTIATE trial, with initial clinical data expected in H2 2025.
The company's third ecDTx program is progressing, targeting a novel kinesin for ecDNA segregation, with development candidate nomination expected by mid-2025 and IND submission planned for H1 2026. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo appointed as Interim CMO. The company's operating runway has been extended into 2027.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and oncogene amplified cancers, has announced its participation in Piper Sandler's 36th Annual Healthcare Conference.
President and CEO Zachary Hornby will participate in a fireside chat on Wednesday, December 4, 2024, at 3:30 p.m. ET in New York. The session will be available via live and archived webcast through the company's website under the Investors section.
Boundless Bio (BOLD) reported Q3 2024 financial results, highlighting progress in its clinical trials. The company maintains a strong cash position of $167.1 million, providing runway into Q4 2026. Key developments include ongoing enrollment in BBI-355 POTENTIATE and BBI-825 STARMAP trials, with initial proof-of-concept data expected in H2 2025. Q3 financials show R&D expenses of $14.1M (up from $11.6M in Q3 2023), G&A expenses of $4.6M (up from $3.3M), and a net loss of $16.5M (increased from $13.2M).
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced its participation in the 2024 Guggenheim Global Healthcare Conference. President and CEO Zachary Hornby will participate in a fireside chat on Tuesday, November 12, 2024, at 2:30 p.m. ET in Boston, MA. The session will be available via live and archived webcast in the Investors section of the company's website under 'Events & Presentations'.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced the departure of CFO Jami Rubin for personal reasons. The company does not plan to hire a successor CFO immediately. David Hinkle, Senior VP of Finance and Controller, will assume responsibility for Finance operations and the roles of principal financial and accounting officer.
CEO Zachary Hornby expressed gratitude for Rubin's contributions, particularly in the company's successful IPO and corporate strategy refinement. Rubin stated her pride in Boundless Bio's accomplishments and confidence in the company's future success, citing ongoing clinical trials for lead programs and a strong balance sheet to support their advancement.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focusing on extrachromosomal DNA (ecDNA) biology, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's executives, Zachary Hornby (President and CEO) and Jami Rubin (CFO), will engage in a fireside chat session on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.
Boundless Bio aims to develop transformative therapies for patients with previously intractable oncogene amplified cancers. Interested parties can access a live and archived webcast of the session through the 'Events & Presentations' section of the company's website under the Investors tab.
Boundless Bio (Nasdaq: BOLD) provided business updates and Q2 2024 financial results. Key points include:
1. BBI-355 POTENTIATE trial ongoing; initial proof-of-concept data now expected in H2 2025.
2. BBI-825 STARMAP trial ongoing; initial data expected in H2 2025.
3. ECHO ecDNA diagnostic validated for use in BBI-355 trial.
4. Operations streamlined to extend runway into Q4 2026.
5. Q2 2024 financials: Cash position $179.3M, R&D expenses $14.7M, G&A expenses $4.7M, Net loss $17.0M.
The company is focusing on core ecDTx programs while scaling back early discovery efforts. Enrollment in BBI-355 combination cohorts is slower than projected, prompting initiatives to accelerate recruitment.
FAQ
What is the current stock price of BOUNDLESS BIO (BOLD)?
What is the market cap of BOUNDLESS BIO (BOLD)?
